Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M141Revenue (TTM) $M54.5Net Margin (%)2.4Altman Z-Score10.2
Enterprise Value $M39.1EPS (TTM) $0.1Operating Margin %6.1Piotroski F-Score7
P/E(ttm)114Beneish M-Score2.1Pre-tax Margin (%)1.8Higher ROA y-yY
Price/Book1.210-y EBITDA Growth Rate %--Quick Ratio9.7Cash flow > EarningsY
Price/Sales2.65-y EBITDA Growth Rate %--Current Ratio10.9Lower Leverage y-yY
Price/Free Cash Flow24.3y-y EBITDA Growth Rate %--ROA % (ttm)1.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)1.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.6ROIC % (ttm)13.8Gross Margin Increase y-yY

Gurus Latest Trades with GENC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GENCJohn Keeley 2010-03-31 Sold Out $6.9 - $7.8
($7.31)
$ 14.79102%Sold Out0
GENCJohn Keeley 2009-09-30 Buy $6.38 - $8.35
($7.23)
$ 14.79105%New holding30,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ELLIOTT MARC Gpresident 2016-06-07Sell15,000$14.91-0.8view
ELLIOTT MARC Gpresident 2016-06-03Sell2,000$14.740.34view
ELLIOTT MARC Gpresident 2016-05-16Sell24,000$14.86-0.47view
Air DavidDirector 2016-03-03Sell5,000$13.410.37view
Houtkin Sherry10% Owner 2016-03-02Sell10,000$13.3810.54view
Houtkin Sherry10% Owner 2016-03-01Sell20,000$13.549.23view
Houtkin Sherry10% Owner 2016-02-26Sell50,000$13.1112.81view
ELLIOTT MARC Gpresident 2016-02-17Sell9,140$12.6816.64view
ELLIOTT MARC GPresident 2015-12-15Sell19,044$12.7416.09view
Houtkin Sherry10% Owner 2015-10-06Sell80,000$9.2659.72view

Quarterly/Annual Reports about GENC:

News about GENC:

Articles On GuruFocus.com
Mario Gabelli Gives Stock Recommendations Feb 26 2016 
Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
“Assign Yourself the Right Story” Mar 05 2012 
Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 
How Long Should You Hold a Net-Net? Feb 13 2012 
Opt-Sciences $OPST- Follow Up Feb 01 2012 
Four Stocks to Fit in a Basket of Negative Enterprise Value with Certain Profitability Dec 23 2011 
Gencor ($GENC)- A free business with a huge portfolio Dec 22 2011 
Genco Industries: $15 Million in Cash and the Company for Free Sep 28 2011 

More From Other Websites
Genmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as... Jun 23 2016
Articles of Association for Genmab A/S Jun 14 2016
Grant of Warrants to Genmab Employees Jun 09 2016
Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q2, 2016 By the Numbers : June 8, 2016 Jun 08 2016
Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis Jun 02 2016
Genmab's Total Number of Voting Rights and Total Share Capital May 31 2016
Genmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Genmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen May 30 2016
Genmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for... May 23 2016
First Participants Dosed in Clinical Study with DuoBody® Product May 20 2016
Articles of Association for Genmab A/S May 19 2016
GENCOR INDUSTRIES INC Financials May 19 2016
Daratumumab and Ofatumumab Data to Be Presented at 21st Congress of EHA May 19 2016
Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or... May 18 2016
Capital Increase in Genmab as a Result of Employee Warrant Exercise May 18 2016
Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for... May 17 2016
Genmab Announces Financial Results for the First Quarter of 2016 May 10 2016
GENCOR INDUSTRIES INC Files SEC form 10-Q, Quarterly Report May 10 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 10 2016
Gencor posts 2Q profit May 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)